Publication:
Disability accrual in primary and secondary progressive multiple sclerosis

dc.contributor.coauthorHarding-Forrester, Sam
dc.contributor.coauthorRoos, Izanne
dc.contributor.coauthorNguyen, Ai-Lan
dc.contributor.coauthorMalpas, Charles B.
dc.contributor.coauthorDiouf, Ibrahima
dc.contributor.coauthorMoradi, Nahid
dc.contributor.coauthorSharmin, Sifat
dc.contributor.coauthorIzquierdo, Guillermo
dc.contributor.coauthorEichau, Sara
dc.contributor.coauthorPatti, Francesco
dc.contributor.coauthorHorakova, Dana
dc.contributor.coauthorKubala Havrdova, Eva
dc.contributor.coauthorPrat, Alexandre
dc.contributor.coauthorGirard, Marc
dc.contributor.coauthorDuquette, Pierre
dc.contributor.coauthorMaison, Francois Grand
dc.contributor.coauthorOnofrj, Marco
dc.contributor.coauthorLugaresi, Alessandra
dc.contributor.coauthorGrammond, Pierre
dc.contributor.coauthorOzakbas, Serkan
dc.contributor.coauthorAmato, Maria Pia
dc.contributor.coauthorGerlach, Oliver
dc.contributor.coauthorSola, Patrizia
dc.contributor.coauthorFerraro, Diana
dc.contributor.coauthorBuzzard, Katherine
dc.contributor.coauthorSkibina, Olga
dc.contributor.coauthorLechner-Scott, Jeannette
dc.contributor.coauthorAlroughani, Raed
dc.contributor.coauthorBoz, Cavit
dc.contributor.coauthorVan Pesch, Vincent
dc.contributor.coauthorCartechini, Elisabetta
dc.contributor.coauthorTerzi, Murat
dc.contributor.coauthorMaimone, Davide
dc.contributor.coauthorRamo-Tello, Cristina
dc.contributor.coauthorYamout, Bassem
dc.contributor.coauthorKhoury, Samia Joseph
dc.contributor.coauthorLa Spitaleri, Daniele
dc.contributor.coauthorSa, Maria Jose
dc.contributor.coauthorBlanco, Yolanda
dc.contributor.coauthorGranella, Franco
dc.contributor.coauthorSlee, Mark
dc.contributor.coauthorButler, Ernest
dc.contributor.coauthorSidhom, Youssef
dc.contributor.coauthorGouider, Riadh
dc.contributor.coauthorBergamaschi, Roberto
dc.contributor.coauthorKarabudak, Rana
dc.contributor.coauthorAmpapa, Radek
dc.contributor.coauthorSanchez-Menoyo, Jose Luis
dc.contributor.coauthorPrevost, Julie
dc.contributor.coauthorCastillo-Trivino, Tamara
dc.contributor.coauthorMcCombe, Pamela A.
dc.contributor.coauthorMacdonell, Richard
dc.contributor.coauthorLaureys, Guy
dc.contributor.coauthorVan Hijfte, Liesbeth
dc.contributor.coauthorOh, Jiwon
dc.contributor.coauthorde Gans, Koen
dc.contributor.coauthorTurkoglu, Recai
dc.contributor.coauthorvan der Walt, Anneke
dc.contributor.coauthorButzkueven, Helmut
dc.contributor.coauthorVucic, Steve
dc.contributor.coauthorBarnett, Michael
dc.contributor.coauthorCristiano, Edgardo
dc.contributor.coauthorHodgkinson, Suzanne
dc.contributor.coauthorIuliano, Gerardo
dc.contributor.coauthorKappos, Ludwig
dc.contributor.coauthorKuhle, Jens
dc.contributor.coauthorShaygannejad, Vahid
dc.contributor.coauthorSoysal, Aysun
dc.contributor.coauthorWeinstock-Guttman, Bianca
dc.contributor.coauthorVan Wijmeersch, Bart
dc.contributor.coauthorKalincik, Tomas
dc.contributor.departmentKUTTAM (Koç University Research Center for Translational Medicine)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorAltıntaş, Ayşe
dc.contributor.schoolcollegeinstituteResearch Center
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-01-19T10:28:15Z
dc.date.issued2023
dc.description.abstractBackground Some studies comparing primary and secondary progressive multiple sclerosis (PPMS, SPMS) report similar ages at onset of the progressive phase and similar rates of subsequent disability accrual. Others report later onset and/or faster accrual in SPMS. Comparisons have been complicated by regional cohort effects, phenotypic differences in sex ratio and management and variable diagnostic criteria for SPMS. Methods We compared disability accrual in PPMS and operationally diagnosed SPMS in the international, clinic-based MSBase cohort. Inclusion required PPMS or SPMS with onset at age >= 18 years since 1995. We estimated Andersen-Gill hazard ratios for disability accrual on the Expanded Disability Status Scale (EDSS), adjusted for sex, age, baseline disability, EDSS score frequency and drug therapies, with centre and patient as random effects. We also estimated ages at onset of the progressive phase (Kaplan-Meier) and at EDSS milestones (Turnbull). Analyses were replicated with physician-diagnosed SPMS. ResultsIncluded patients comprised 1872 with PPMS (47% men; 50% with activity) and 2575 with SPMS (32% men; 40% with activity). Relative to PPMS, SPMS had older age at onset of the progressive phase (median 46.7 years (95% CI 46.2-47.3) vs 43.9 (43.3-44.4); p<0.001), greater baseline disability, slower disability accrual (HR 0.86 (0.78-0.94); p<0.001) and similar age at wheelchair dependence. Conclusions We demonstrate later onset of the progressive phase and slower disability accrual in SPMS versus PPMS. This may balance greater baseline disability in SPMS, yielding convergent disability trajectories across phenotypes. The different rates of disability accrual should be considered before amalgamating PPMS and SPMS in clinical trials.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue9
dc.description.openaccessGreen Published
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipThis study was financially supported by the National Health and Medical Research Council of Australia (1129189, 1140766). The MS Base Foundation is a not- for- profit organisation that has received support from Biogen, CSL, Merck, Novartis, Roche, Sanofi and Teva; this study was conducted independently of the sponsors.
dc.description.volume94
dc.identifier.doi10.1136/jnnp-2022-330726
dc.identifier.eissn1468-330X
dc.identifier.issn0022-3050
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85160248113
dc.identifier.urihttps://doi.org/10.1136/jnnp-2022-330726
dc.identifier.urihttps://hdl.handle.net/20.500.14288/25673
dc.identifier.wos989489100001
dc.keywordsMultiple sclerosis
dc.language.isoeng
dc.publisherBMJ Publishing Group
dc.relation.grantnoNational Health and Medical Research Council of Australia [1129189, 1140766]; Biogen; CSL; Merck; Novartis; Roche; Teva; Sanofi
dc.relation.ispartofJournal of Neurology Neurosurgery and Psychiatry
dc.subjectClinical neurology
dc.subjectPsychiatry
dc.subjectSurgery
dc.titleDisability accrual in primary and secondary progressive multiple sclerosis
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorAltıntaş, Ayşe
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1Research Center
local.publication.orgunit2KUTTAM (Koç University Research Center for Translational Medicine)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublication91bbe15d-017f-446b-b102-ce755523d939
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscovery91bbe15d-017f-446b-b102-ce755523d939
relation.isParentOrgUnitOfPublicationd437580f-9309-4ecb-864a-4af58309d287
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscoveryd437580f-9309-4ecb-864a-4af58309d287

Files